Immutep Expands Part B of TACTI-002 Study
05 mars 2021 08h00 HE
|
Immutep Limited
Sydney, AUSTRALIA, March 05, 2021 (GLOBE NEWSWIRE) -- – Immutep Limited (ASX: IMM; NASDAQ: IMMP) a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases,...